Network News

Zwingenberg, Germany, 4 February 2025 – Akribion Therapeutics (“Akribion”), the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announces its exit from stealth and the completion of a Seed Financing round raising EUR 8 million to accelerate the development of novel therapeutics based on Akribion’s proprietary G-dase® E nucleases. The round […]

Uppsala, Sweden, 05 February 2025: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers, today announced the introduction of its Gyrolab® HEK293 HCP Type SN Kit Reagents and Gyrolab HEK293 HCP Type CL Kit Reagents. Developed with antibodies from BioGenes GmbH, a global leader in host cell protein (HCP) assay […]

The research of BioMed X team EDC – Extrachromosomal DNA in Cancer – has uncovered critical insights into the mechanisms driving extrachromosomal DNA (ecDNA) formation and maintenance, offering potential avenues for novel cancer therapies. Heidelberg, Germany, February 6, 2025. BioMed X, a German independent research institute, announces the successful completion of its oncology research project in partnership […]

Dr. Paul Naser from the Department of Neurosurgery at Heidelberg University Hospital and the Heidelberg Faculty of Medicine at Heidelberg University has been awarded the German Society for Neurointensive and Emergency Medicine (DGNI) Young Investigator Award. The prize is endowed with 20,000 euros in funding. He receives the prize for a research project that aims […]

Three institutions have joined our consortium as official Chemoproteomics and Spatial Mass Spectrometry (MS)-Based Omics partner sites, enhancing the services we can offer to the research community in the areas of target identification and validation. Phil Gribbon, Director General of EU-OPENSCREEN, emphasised: “The three new chemoproteomics sites joining the EU-OPENSCREEN partner network provide a significant boost […]

Artificial Intelligence (AI) is transforming cancer prevention: A groundbreaking study conducted at the German Cancer Research Center (DKFZ) demonstrates that AI-generated social media influencers can effectively reach at-risk groups with preventive health messages—at a fraction of the cost of traditional campaigns. In this pilot study, researchers created a virtual influencer named “Wanda” who shared educational […]

Braunschweig, January 29th, 2025 – YUMAB GmbH, a German biotechnology company specializing in contract research for therapeutic antibodies, announces its collaboration with InSCREENeX GmbH to establish a novel technology for antibody development. As part of the funded project “Mammalian Display,” the two Braunschweig-based companies are developing a platform that enables the screening of antibody libraries […]

Menarini Biotech (MBH) is a leading CDMO specializing in Process Development and GMP manufacturing across various therapeutic areas. With a mission to be a reliable, agile, and innovative partner, MBH empowers its customers to bring life-saving biotherapeutics to patients through expertise in drug development. From lab to production, cutting-edge technology accelerates processes, optimizes yields, and […]

At GeneTechX, they are developing a nutrigenomics platform that combines genetics and nutritional science to create personalized dietary solutions. Leveraging advanced gene-editing technologies like PrimeCRISPR, they investigate the intricate relationships between genes, diet, and health outcomes. By identifying genetic variations that affect nutrient metabolism, GeneTechX delivers tailored nutrition strategies to enhance health and prevent disease, […]